Outlook 2021 – Washington, D.C. Updates and Insights on Life Sciences and Health Care

Practices: Health Care, Life Sciences

As a new administration enters the White House, businesses and investors are preparing for potential regulatory and compliance changes. Please join us for a discussion of the most noteworthy developments and issues emanating from DC and their potential impact on life sciences and health care companies in 2021.

Part 1: Focus on FDA – 12:30pm – 1:15pm
Topics of discussion will include:

  • FDA leadership changes, policy priorities and related legislation
  • Digital Health: Real World Evidence, Artificial Intelligence and Machine-Based Learning
  • Anticipated shifts in FDA enforcement priorities

Part 2: Focus on HHS – 1:15pm – 2:00pm
Topics of discussion will include:

  • Changes in HHS/CMS/OIG priorities, including The Affordable Care Act
  • Most Favored Nation rule and other drug pricing prospects
  • Congressional Review Act possibilities
  • Provider Relief Fund auditing activity

For more resources and insights related to the new administration, please visit our online hub, Capital Insights.

Cookie Settings